The RNA-Based Vaccine Market is strongly supported by applications targeting infectious diseases. The infectious-disease segment currently represents a major portion of demand because RNA platforms can potentially be adapted rapidly to address emerging pathogens.

Cancer immunotherapy is becoming an increasingly important application area. Researchers are investigating RNA-based vaccines that can stimulate immune responses against tumor-specific or tumor-associated antigens, supporting the broader movement toward personalized cancer treatment.

Autoimmune diseases represent another emerging opportunity. RNA technologies are being studied for their potential to modulate immune responses in a more targeted manner.